Ingredient guide · Ingredient reference

Vitamin E in PIVENS: improved liver histology did not mean fibrosis reversal

PIVENS found a benefit on its composite liver-histology outcome in selected adults without diabetes. Fibrosis scores did not significantly improve.

Read the evidence ↓

Supplement Science Insights Editorial Team

Published September 23, 2026

Evidence and findings

The trial randomized 247 adults with nonalcoholic steatohepatitis to vitamin E, pioglitazone or placebo for ninety-six weeks. Vitamin E improved the primary histologic outcome in 43 percent versus 19 percent with placebo. [1]

Liver enzymes and some inflammatory or fat-related histology measures improved, but the fibrosis comparison was not significant. The trial’s prespecified significance threshold also mattered when interpreting its two primary comparisons. [1]

Interpretation and limits

This population does not represent every person with fatty liver, diabetes or cirrhosis. NIH grants are listed in the retrieved record; complete funding and conflict disclosures were not established from the abstract. The trial does not provide a universal self-treatment regimen. [1]

A hypothetical distinction

Imagine a composite outcome improves through several components while fibrosis does not. Calling that result fibrosis reversal would misstate the evidence.

Evidence summary — Vitamin E in PIVENS
DetailInterpretation
Composite improvementDefined trial outcome
FibrosisSeparate nonsignificant result
Other populationsNeed separate evidence
Vitamin E in PIVENS: improved liver histology did not mean fibrosis reversal — original article outline diagram
Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

Sources for this article

  1. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis - PubMed
    Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.